Will Teva's Play Usher Generic, Biosimilar Makers Into "Innovator" Territory?

PhRMA is facing a controversial, potentially industry-altering decision. The generics king Teva has requested to become a member of the trade organization that traditionally represents “innovators”.

Teva’s request to join has raised some eyebrows at PhRMA — though this reaction should not come as a surprise. Since the launch of small-molecule generics decades ago, generics makers have been pitted against innovators and their patents for space in the market. Today, this division continues to be further emphasized as biosimilar makers begin battling biologics for a more timely market release. As such, Teva’s potential admittance to PhRMA is, to some members, akin to “a spy” entering the ranks, The New York Times reports. As one expert from a PhRMA member company tells the NYT, “Teva has sought to invalidate patents in 29 cases since 2011,” a fact which he says calls into question “Teva’s commitment to innovation.”

But Teva’s request highlights a key shift within the industry that has only been accentuated by the arrival of biosimilars.

Continue reading on Biosimilar Development: https://www.biosimilardevelopment.com/doc/will-teva-s-play-usher-generic-biosimilar-makers-into-innovator-territory-0001